The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Zoldonrasib and daraxonrasib in pre-treated KRAS G12D metastatic PDAC
Teresa Macarulla, MD, Vall d’Hebron University Hospital, Barcelona, Spain, describes preliminary safety and efficacy findings from a Phase I study (NCT06040541) of zoldonrasib and daraxonrasib, two oral RAS(ON) inhibitors, in patients with previously treated KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma (PDAC). In the trial, the doublet showed a manageable safety profile and encouraging antitumor activity. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
